載入中
Xenon Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company dedicated to discovering and advancing innovative treatments for individuals living with neurological disorders. The company operates primarily from its headquarters in Burnaby, Canada. Its robust clinical pipeline showcases several promising candidates: XEN496, an activator of Kv7 potassium channels, is currently in Phase III clinical trials for KCNQ2 developmental and epileptic encephalopathy. Another Kv7 potassium channel activator, XEN1101, is progressing through Phase II trials, targeting epilepsy and a range of other neurological conditions. The portfolio also includes NBI-921352, a selective inhibitor of the Nav1.6 sodium channel, which is undergoing Phase II clinical evaluation for SCN8A developmental and epileptic encephalopathy, alongside investigations for adult focal epilepsy and other potential indications. Furthermore, XEN007, a central nervous system-acting calcium channel modulator, is also in Phase II development. Beyond its internal development, Xenon Pharmaceuticals has established strategic collaborations. This includes a licensing and development agreement with Neurocrine Biosciences, Inc. focused on epilepsy treatments, and a partnership with Flexion Therapeutics, Inc. to advance PCRX301 (also known as XEN402), a Nav1.7 inhibitor, for post-operative pain management. Established in 1996, the company continues its mission to address significant unmet medical needs in neurology.
前收盤價
US$36.44
+US$0.28 · +0.77%
盤中時間採用ET。市場資料可能有所延遲。
Xenon Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company dedicated to discovering and advancing innovative treatments for individuals living with neurological disorders. The company operates primarily from its headquarters in Burnaby, Canada. Its robust clinical pipeline showcases several promising candidates: XEN496, an activator of Kv7 potassium channels, is currently in Phase III clinical trials for KCNQ2 developmental and epileptic encephalopathy. Another Kv7 potassium channel activator, XEN1101, is progressing through Phase II trials, targeting epilepsy and a range of other neurological conditions. The portfolio also includes NBI-921352, a selective inhibitor of the Nav1.6 sodium channel, which is undergoing Phase II clinical evaluation for SCN8A developmental and epileptic encephalopathy, alongside investigations for adult focal epilepsy and other potential indications. Furthermore, XEN007, a central nervous system-acting calcium channel modulator, is also in Phase II development. Beyond its internal development, Xenon Pharmaceuticals has established strategic collaborations. This includes a licensing and development agreement with Neurocrine Biosciences, Inc. focused on epilepsy treatments, and a partnership with Flexion Therapeutics, Inc. to advance PCRX301 (also known as XEN402), a Nav1.7 inhibitor, for post-operative pain management. Established in 1996, the company continues its mission to address significant unmet medical needs in neurology.
日內區間
目前US$36.44
52週區間
目前US$36.44
盤中時間採用ET。市場資料可能有所延遲。
Xenon Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company dedicated to discovering and advancing innovative treatments for individuals living with neurological disorders. The company operates primarily from its headquarters in Burnaby, Canada. Its robust clinical pipeline showcases several promising candidates: XEN496, an activator of Kv7 potassium channels, is currently in Phase III clinical trials for KCNQ2 developmental and epileptic encephalopathy. Another Kv7 potassium channel activator, XEN1101, is progressing through Phase II trials, targeting epilepsy and a range of other neurological conditions. The portfolio also includes NBI-921352, a selective inhibitor of the Nav1.6 sodium channel, which is undergoing Phase II clinical evaluation for SCN8A developmental and epileptic encephalopathy, alongside investigations for adult focal epilepsy and other potential indications. Furthermore, XEN007, a central nervous system-acting calcium channel modulator, is also in Phase II development. Beyond its internal development, Xenon Pharmaceuticals has established strategic collaborations. This includes a licensing and development agreement with Neurocrine Biosciences, Inc. focused on epilepsy treatments, and a partnership with Flexion Therapeutics, Inc. to advance PCRX301 (also known as XEN402), a Nav1.7 inhibitor, for post-operative pain management. Established in 1996, the company continues its mission to address significant unmet medical needs in neurology.
日內區間
目前US$36.44
52週區間
目前US$36.44
獲利能力占已公布營收的百分比。
營收
營業利益
淨利
| 項目（USD） | 2025會計年度 | 2024會計年度 | 2023會計年度 | 2022會計年度 | 2021會計年度 |
|---|---|---|---|---|---|
| 營收 | 750萬 USD | — | — | 943.4萬 USD | 1843.7萬 USD |
| 銷貨成本 | 254.3萬 USD | 256萬 USD | 1.68億 USD | — | — |
| 毛利 | 495.7萬 USD | −256萬 USD | −1.68億 USD | 943.4萬 USD | 1843.7萬 USD |
| 研究與開發 | 3.01億 USD | 2.1億 USD | 1.68億 USD | 1.06億 USD | 7546.3萬 USD |
| 銷售、一般及管理費用 | 7963.2萬 USD | 6890.4萬 USD | 4654.2萬 USD | 3281萬 USD | 2196.7萬 USD |
| 營業費用 | 3.78億 USD | 2.77億 USD | 4654.2萬 USD | 1.39億 USD | 9743萬 USD |
| 利息收入 | 2682.8萬 USD | 4194.3萬 USD | 2762萬 USD | 871.3萬 USD | 46.6萬 USD |
| 折舊和攤銷 | 254.3萬 USD | 256萬 USD | 354.1萬 USD | 140.5萬 USD | 90.6萬 USD |
| 營業利益 | −3.73億 USD | −2.79億 USD | −2.14億 USD | −1.29億 USD | −7899.3萬 USD |
| 淨利 | −3.46億 USD | −2.34億 USD | −1.82億 USD | −1.25億 USD | −7888.2萬 USD |
公司資料更新於 2026年10月11日。
近期已公布業績
近期已公布業績
第三方分析師預期可能變動，並非 GoAI 建議。
平均目標
US$68.63
上漲空間 88.34%報告持有此股票曝險的交易所交易基金。
iShares Russell 2000 ETFIWM9330.19萬0.12%787.4億 USD0.19%US$278.94+0.49%
Vanguard Russell 2000 ETFVTWO3397.79萬0.18%180億 USD0.06%US$112.66+0.50%
iShares Russell 2000 Growth ETFIWO3277.7萬0.24%139.17億 USD0.24%US$356.78+0.94%
iShares Biotechnology ETFIBB2572.42萬0.24%108.2億 USD0.44%US$206.49+3.00%
T. Rowe Capital Appreciation Equity ETFTCAF2030.96萬0.23%91.1億 USD0.31%US$43.59+0.90%
Vanguard Russell 2000 Growth ETFVTWG645.29萬0.37%17億 USD0.06%US$260.49+0.91%
State Street SPDR Portfolio Developed World ex-US ETFSPDW549.15萬0.01%404.62億 USD0.03%US$49.98+0.64%
Fidelity Enhanced Small Cap ETFFESM518.77萬0.08%64.1億 USD0.28%US$45.46+0.46%iShares Russell 2000 ETFIWMVanguard Russell 2000 ETFVTWOiShares Russell 2000 Growth ETFIWOiShares Biotechnology ETFIBBT. Rowe Capital Appreciation Equity ETFTCAFVanguard Russell 2000 Growth ETFVTWGState Street SPDR Portfolio Developed World ex-US ETFSPDWFidelity Enhanced Small Cap ETFFESMAI 生成內容及延遲市場資料僅供資訊與教育用途，不構成投資建議。
